Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Rhythm Pharmaceuticals (NASDAQ:RYTM) Inc on Tuesday, setting a price target of $37, which is approximately 62.28% above the present share price of $22.8.
Lee expects Rhythm Pharmaceuticals Inc to post earnings per share (EPS) of -$0.71 for the fourth quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Rhythm Pharmaceuticals, with an average price target of $39.5.
The analysts price targets range from a high of $43 to a low of $36.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $0 and a net profit of -$31.92 million. The company's market cap is $1.01 billion.
According to TipRanks.com, Canaccord Genuity analyst Arlinda Lee is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 4.7% and a 48.41% success rate.
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.